Rezvilutamide

Rezvilutamide (INN;[1][2] developmental code name SHR3680) is a nonsteroidal antiandrogen which is under development by Jiangsu Hengrui Medicine for the treatment of prostate cancer and breast cancer.[3][4] It is a selective androgen receptor antagonist with reduced brain distribution compared to the structurally related nonsteroidal antiandrogen enzalutamide.[3][4] As of October 2020, rezvilutamide is in phase 3 clinical trials for prostate cancer.[3] Other structural analogues of rezvilutamide besides enzalutamide include apalutamide and proxalutamide.

Rezvilutamide

Clinical data
Other names	SHR3680
Drug class	Nonsteroidal antiandrogen
Identifiers
IUPAC name 4-[3-[4-[(2S)-2,3-dihydroxypropoxy]phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
CAS Number	1572045-62-5
PubChem CID	89995232
UNII	70FJN2AW22
Chemical and physical data
Formula	C22H20F3N3O4S
Molar mass	479.47 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CC1(C(=O)N(C(=S)N1C2=CC=C(C=C2)OC[C@H](CO)O)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
InChI InChI=1S/C22H20F3N3O4S/c1-21(2)19(31)27(15-4-3-13(10-26)18(9-15)22(23,24)25)20(33)28(21)14-5-7-17(8-6-14)32-12-16(30)11-29/h3-9,16,29-30H,11-12H2,1-2H3/t16-/m0/s1 Key:KRBMOYIWQCZVHA-INIZCTEOSA-N

See also

• List of investigational hormonal agents § Androgenics

References

1. "Rezvilutamide". chemidplus. U.S. National Library of Medicine.
2. "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO.
3. "SHR 3680". AdisInsight.
4. Qin X, Han W, Luo H, Du C, Zou Q, Sun Z, et al. (2020). "SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study". Journal of Clinical Oncology. 38 (6_suppl): 90. doi:10.1200/JCO.2020.38.6_suppl.90.